Gender-neutral HPV elimination, cervical cancer screening, and treatment: Experience from Bhutan.
Thinley DorjiUgyen TshomoSonam GyamtshoSaran Tenzin TamangSangay WangmoKrit PongpirulPublished in: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2021)
Cervical cancer is preventable and also curable when detected early and treated adequately, yet it remains a leading cause of morbidity and mortality among women. In Bhutan, cervical cancer is the most common cancer among women. Bhutan was the first country among the low- and middle-income economies to have instituted a national HPV vaccination program, in 2010, and has achieved >90% coverage. In 2019, Bhutan launched a cervical cancer elimination flagship program well ahead of WHO's launch of the global strategy for accelerated elimination of cervical cancer. Bhutan initiated vaccination of adolescent boys and adopted a gender-neutral vaccination program beginning September 2020 through its well-established network of primary healthcare centres. The flagship program aims to screen women aged 30-69 years with HPV testing using liquid-based cytology (LBC) as triaging for screen positive women. For women aged 25-29 years, LBC will be continued as per American Society of Colposcopy and Cervical Pathology guidelines. Colposcopy and treatment will be performed in camps to decrease loss of follow up of screen positive women. This program is also expected to improve early diagnosis of cervical cancer and provide timely and adequate cancer treatment and palliative care services. This article reviews the progress made and the challenges facing the 2030 cervical cancer elimination targets in Bhutan.
Keyphrases
- cervical cancer screening
- polycystic ovary syndrome
- quality improvement
- healthcare
- pregnancy outcomes
- palliative care
- mental health
- high grade
- insulin resistance
- breast cancer risk
- primary care
- high throughput
- type diabetes
- emergency department
- randomized controlled trial
- physical activity
- metabolic syndrome
- clinical practice
- single cell
- combination therapy
- pregnant women
- lymph node metastasis
- skeletal muscle
- health insurance
- drug induced
- advanced cancer
- smoking cessation